In the Rotterdam arm of the ERSPC, we found that the panel resulted in a similar improvement in predictive accuracy (AUC improved from 0.64 to 0.76) and reduction of biopsy rates (573 per 1000 men with elevated PSA) while missing only a small number of cancers (42 per 1000 men) [9]. Here, KLK3 is linked to cancer.